Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization in the isolated rabbit heart

Journal of Cardiovascular Pharmacology

Volumn 34, Issue 1, 1999, Pages 82-88

  Drici, M D ^a   Ebert, S N ^a   Wang, W X ^a   Rodriguez, I ^a   Liu, X K ^a   Whitfield, B H ^a   Woosley, R L ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cisapride; Gastrointestinal motility disorders; Tegaserod; Torsades de pointes

Indexed keywords

5 METHOXY INDOLE 3 CARBOXYLIC ACID GLUCURONIDE; CISAPRIDE; DRUG METABOLITE; ERYTHROMYCIN; INDOLE DERIVATIVE; SDZ 244120; TEGASEROD; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; HEART PERFUSION; HEART REPOLARIZATION; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL; RABBIT;

ANIMALS; CISAPRIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; ERYTHROMYCIN; FEMALE; GASTROINTESTINAL AGENTS; HEART; INDOLES; PERFUSION; RABBITS;

EID: 0033033084     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199907000-00014     Document Type: Article

References (39)

1. Carlsson L, Amgren O, Duker G. QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology and interventions. J Cardiovasc Pharmacol 1990;16:276-85.
2. Faber T, Zehender M, Just H. Drug-induced torsades de pointes. Drug Safety 1994;11:463-76.
3. Goodman J, Peter C. Proarrhythmia: primum non nocere. In: Mandel W, ed. Cardiac arrhythmias (their mechanisms, diagnosis, and management). Philadelphia: JB Lippincott, 1995:173-91.
4. Janssens J, Peters T, Vantrappen G, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. N Engl J Med 1990;322:1028-31.
5. Weber F, Richards R, McCallum R. Erythromycin: a motilin agonist and gastrointestinal prokinetic agent. Am J Gastroenterol 1993;88:485-90.
6. Wong SL, Cao G, Mack RJ, Granneman GR. The effect of erythromycin on the CYP3A component of sertindole clearance in healthy volunteers. J Clin Pharmacol 1997;37:1056-61.
7. Fisman S, Reniers D, Diaz P. Erythromycin interaction with risperidone or clomipramine in an adolescent. J Child Adolesc Psychopharmacol 1996;6:133-8.
8. Zhang XJ, Thomas PE. Erythromycin as a specific substrate for cytochrome P4503A isozymes and identification of a high-affinity erythromycin N-demethylase in adult female rats. Drug Metab Dispos 1996;24:23-7.
9. Stafstrom CE, Nohria V, Loganbill H, Nahouraii R, Boustany RM, De Long GR. Erythromycin-induced carbamazepine toxicity: a continuing problem. Arch Pediatr Adolesc Med 1995;149:99-101.
10. Antzelevitch C, Sun ZQ, Zhang ZQ, Yan GX. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsades de pointes. J Am Coll Cardiol 1996;28:1836-48.
11. Daleau P, Lessard E, Groleau MF, Turgeon J. Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes. Circulation 1995;91:3010-6.
12. Nattel S, Ranger S, Talajic M, Lemery R, Roy D. Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism. Am J Med 1990; 89:235-8.
13. Farrar H, Walsh-Sukys M, Kyllonen K, Blumer J. Cardiac toxicity associated with intravenous erythromycin lactobionate: two case reports and a review of the literature. Pediatr Infect Dis J 1993; 12:688-91.
14. Ahmad S. Cisapride and torsades de pointes. Lancet 1995;345:508.
15. Bran S, Murray WA, Hirsch IB, Palmer JP. Long QT syndrome during high-dose cisapride. Arch Intern Med 1995;155:765-8.
16. Carlsson L, Amos GJ, Andersson B, Drews L, Duker G, Wadstedt G. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential? J Pharmacol Exp Ther 1997;282:220-7.
17. Puisieux FL, Adamantidis MM, Dumotier BM, Dupuis BA. Cisapride-induced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibres. Br J Pharmacol 1996;117:1377-9.
18. Ku Y, Ito T. Effects of 5-HT4-receptor agonists, cisapride, mosapride citrate, and zacopride, on cardiac action potentials in guinea pig isolated papillary muscles. J Cardiovasc Pharmacol 1997;29:670-5.
19. Nguyen A, Camilleri M, Kost LJ, et al. SDZ HTF 919 stimulates canine colonic motility and transit in vivo. J Pharmacol Exp Ther 1997;280:1270-6.
20. Appel S, Kumle A, Meier R. Clinical pharmacodynamics of SDZ HTF 919: a new 5-HT4 receptor agonist, in a model of slow colonie transit. Clin Pharmacol Ther 1997;62:546-55.
21. Fioramonti J, Million M, Bueno L. Investigations on a 5HT4 agonist (SDZ HTF 919) and its main metabolite in conscious dogs: effects on gastrointestinal motility and impaired gastric emptying. Gastroenterology 1998;114:A752.
22. 4 receptors. Naunyn Schmiedebergs Arch Pharmacol 1998;357:R29.
23. Pfannkuche H-J, Buhl T, Gamse R, Hoyer D, Mattes H, Bucheit K-H. The properties of a new prokinetically active drug, SDZ HTF 919. Neurogastroenterol Motil 1995;7:280.
24. Liu X-K, Katchman A, Drici M-D, et al. Gender difference in the cycle length-dependent QT and potassium currents in rabbits. J Pharmacol Exp Ther 1998;285:672-9.
25. Wang W-X, Ebert SN, Liu X-K, Chen Y-W, Drici M-D, Woosley RL. "Conventional" antihistamines slow cardiac repolarization in isolated perfused (Langendorff) feline hearts. J Cardiovasc Pharmacol 1998;32:123-8.
26. Drici MD, Burklow TR, Haridasse V, Glazer RI, Woosley RL. Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. Circulation 1996;94: 1471-4.
27. Spinelli W, Moubarak IF, Parsons RW, Colatsky TJ. Cellular electrophysiology of WAY-123,398, a new class III antiarrhythmic agent: specificity of IK block and lack of reverse use dependence in cat ventricular myocytes. Cardiovasc Res 1993;27:1580-91.
28. Van Peer A, Verlinden M, Woestenborghs R, Meuldermans W, Heykants J, Reyntjens A. Clinical pharmacokinetics of cisapride. In: Johnson A, Lux G, eds. Progress in the treatment of gastrointestinal motility disorders: the role of cisapride. New York: Exerpta Medica, 1988;23-9.
29. Wiseman LR, Faulds D. Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 1994;47:116-52.
30. Zabel M, Hohnloser SH, Behrens S, Woosley RL, Franz MR. Differential effects of D-sotalol, quinidine, and amiodarone on dispersion of ventricular repolarization in the isolated rabbit heart. J Cardiovasc Electrophysiol 1997;8:1239-45.
31. Fedida D, Giles WR. Regional variations in action potentials and transient outward current in myocytes isolated from rabbit left ventricle. J Physiol (Lond) 1991;442:191-209.
32. Giles WR, Imaizumi Y. Comparison of potassium currents in rabbit atrial and ventricular cells. J Physiol (Lond) 1988;405:123-45.
33. Woosley RL. Cardiac actions of antihistamines. Annu Rev Pharmacol Toxicol 1997;36:233-52.
34. Wysowski D, Bacsayni J. Cisapride and fatal arrhythmia. N Engl J Med 1996;335:290-1.
35. Gitler B, Berger LS, Buffa SD. Torsades de pointes induced by erythromycin. Chest 1994;105:368-72.
36. Austin KL, Mather LE, Philpot CR, McDonald PJ. Intersubject and dose-related variability after intravenous administration of erythromycin. Br J Clin Pharmacol 1980;10:273-9.
37. Henry J, Turner P, Garland M, Esmieu F. Plasma and salivary concentrations of erythromycin after administration of three different formulations. Postgrad Med J 1980;56:707-10.
38. Ponsonnaille J, Citron B, Richard A, et al. Electrophysiological study of pro-arrhythmogenic effects of erythromycin. Arch Mal Coeur Vaiss 1988;81:1001-8.
39. Harkness JE. Clinical procedures. In: Wagner JE, ed. Biology and medicine of rabbits and rodents. Media, PA: Williams & Wilkins, 1995:75-142.